PALM BEACH GARDENS, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced that the company will be participating in two upcoming investor conferences.
ZimVie will be presenting at the upcoming Stifel 2024 Jaws & Paws Conference. ZimVie’s management is scheduled to present on Thursday, May 30, 2024, at 11:30 a.m. Eastern Time.
ZimVie’s management will also be presenting at the 45th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 12, 2024, at 3:20 p.m. Eastern Time.
Interested parties may access a live audio webcast of the presentations by visiting the “Investors” section of the company’s website at investor.zimvie.com.
About ZimVie
ZimVie is a global life sciences leader in the dental market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life. For more information about ZimVie, please visit us at www.ZimVie.com. Follow @ZimVie on Twitter, Facebook, LinkedIn, or Instagram.
Media Contact Information:
ZimVie
Allison Johnson • This email address is being protected from spambots. You need JavaScript enabled to view it.
(774) 266-8046
ZimVie
Grace Flowers • This email address is being protected from spambots. You need JavaScript enabled to view it.
(561) 319-6130
Investor Contact Information:
Gilmartin Group LLC
Marissa Bych • This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$13.50 |
Daily Change: | -0.45 -3.23 |
Daily Volume: | 196,581 |
Market Cap: | US$372.600M |
October 30, 2024 October 29, 2024 August 01, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB